Revolution Medicines (RVMD) Prepaid Assets (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Prepaid Assets of $59.8 million for Q1 2026, up 87.51% year-over-year from $31.9 million in Q1 2025, and up 21.21% quarter-over-quarter from $49.4 million in Q4 2025.
Revolution Medicines (RVMD) Prepaid Assets (2019 - 2026) Analysis & Trends
Revolution Medicines' Prepaid Assets history runs 8 years deep, the most recent figure standing at $59.8 million for Q1 2026.
- In Q1 2026, Prepaid Assets rose 87.51% year-over-year to $59.8 million; the TTM figure through Mar 2026 stood at $59.8 million (up 87.51% YoY), while the FY2025 annual figure was $49.4 million, up 28.76% from the prior year.
- Prepaid Assets for Q1 2026 stood at $59.8 million, up from $49.4 million in the prior quarter.
- The five-year high for Prepaid Assets was $59.8 million in Q1 2026, with the low at $9.0 million in Q1 2023.
- The 5-year median for Prepaid Assets is $25.7 million (2024), against an average of $27.1 million.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets plunged 36.88% in 2023, then jumped 237.02% in 2024.
- Revolution Medicines' Prepaid Assets stood at $10.6 million in 2022, then soared by 137.22% to $25.1 million in 2023, then surged by 52.89% to $38.3 million in 2024, then advanced by 28.76% to $49.4 million in 2025, then gained by 21.21% to $59.8 million in 2026.
- Business Quant data shows RVMD's Prepaid Assets at $59.8 million in Q1 2026, $49.4 million in Q4 2025, and $46.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.37 Mn |
| Mar 31, 2026 | 59.83 Mn |
| Dec 31, 2025 | 49.36 Mn |
| Sep 30, 2025 | 45.98 Mn |
| Jun 30, 2025 | 39.27 Mn |
| Mar 31, 2025 | 31.91 Mn |
| Dec 31, 2024 | 38.33 Mn |
| Sep 30, 2024 | 29.66 Mn |
| Jun 30, 2024 | 34.02 Mn |
| Mar 31, 2024 | 25.66 Mn |
| Dec 31, 2023 | 25.07 Mn |
| Sep 30, 2023 | 10.96 Mn |
| Jun 30, 2023 | 10.09 Mn |
| Mar 31, 2023 | 8.96 Mn |
| Dec 31, 2022 | 10.57 Mn |
| Sep 30, 2022 | 15.16 Mn |
| Jun 30, 2022 | 15.99 Mn |
| Mar 31, 2022 | 10.21 Mn |
| Dec 31, 2021 | 6.79 Mn |
| Sep 30, 2021 | 7.47 Mn |